Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Indatuximab Ravtansine (BT062) In Combination With Lenalidomide and Low-Dose Dexamethasone In Patients With Relapsed and/Or Refractory Multiple Myeloma: Clinical Activity In Len/Dex-Refractory Patients

Kevin R. Kelly, MD, PhD, Asher Chanan-Khan, MD, George Somlo, MD, Leonard T Heffner, MD, David S Siegel, MD, PhD., Todd M Zimmerman, MD, Sundar Jagannath, MD, Nikhil C. Munshi, MD, Sagar Lonial, M.D., Vivek Roy, M.D., Markus Ruehle, MD, Shailesh Chavan, MD, Pankaj Patel, PhD, Markus Rothenburger, MD, Andrea Wartenberg-Demand, MD, Thomas Haeder, PhD, Kenneth C. Anderson

Blood (2013) 122 (21): 758.

https://doi.org/10.1182/blood.V122.21.758.758

Published: 2013

Journal Articles

BT062, an Antibody-Drug Conjugate Directed Against CD138, Given Weekly for 3 Weeks in Each 4 Week Cycle: Safety and Further Evidence of Clinical Activity

Leonard T Heffner, MD, Sundar Jagannath, MD, Todd M Zimmerman, MD, Kelvin P Lee, MD, Jacalyn Rosenblatt, MD, Sagar Lonial, MD, Robert J. Lutz, PhD, Niklas Czeloth, PhD, Frank Osterroth, PhD, Markus Ruehle, MD, Michelle A. Beelitz, Andrea Wartenberg-Demand, MD, Thomas Haeder, PhD, Kenneth C. Anderson, MD, Nikhil C. Munshi, MD

Blood (2012) 120 (21): 4042.

https://doi.org/10.1182/blood.V120.21.4042.4042

Published: 2012

Journal Articles

BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

Sundar Jagannath, MD, Asher Chanan-Khan, MD, Leonard T. Heffner, MD, David Avigan, MD, Todd M. Zimmerman, MD, Sagar Lonial, MD, Robert J. Lutz, PhD, Andre Engling, PhD, Christoph Uherek, PhD, Frank Osterroth, PhD, Markus Ruehle, MD, Michelle A. Beelitz, Gabriele Niemann, PhD, Andrea Wartenberg-Demand, MD, Thomas Haeder, PhD, Kenneth C. Anderson, MD, Nikhil C. Munshi, MD

Blood (2011) 118 (21): 305.

https://doi.org/10.1182/blood.V118.21.305.305

Published: 2011

Journal Articles

BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity In a Phase I Study In Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

Sundar Jagannath, MD, Asher A. Chanan-Khan, MD, Leonard T Heffner, MD, David Avigan, MD, Robert J Lutz, PhD, Christoph Uherek, PhD, Frank Osterroth, PhD, Markus Ruehle, MD, Thomas Haeder, PhD, Gabriele Niemann, PhD, Andrea Wartenberg-Demand, MD, Nikhil C. Munshi, MD, Kenneth C. Anderson

Blood (2010) 116 (21): 3060.

https://doi.org/10.1182/blood.V116.21.3060.3060

Published: 2010

Journal Articles

Phase I Study of BT062 Given as Repeated Single Dose Once Every 3 Weeks in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma.

Asher A. Chanan-Khan, MD, Sundar Jagannath, MD, Leonard T. Heffner, David Avigan, MD, Kelvin P. Lee, MD, Robert J Lutz, PhD, Thomas Haeder, PhD, Markus Ruehle, MD, Christoph Uherek, PhD, Andrea Barbara Wartenberg-Demand, MD, Nikhil Munshi, Kenneth C. Anderson, MD

Blood (2009) 114 (22): 1862.

https://doi.org/10.1182/blood.V114.22.1862.1862

Published: 2009

NARROW

Indatuximab Ravtansine (BT062) In Combination With Lenalidomide and Low-Dose Dexamethasone In Patients With Relapsed and/Or Refractory Multiple Myeloma: Clinical Activity In Len/Dex-Refractory Patients

BT062, an Antibody-Drug Conjugate Directed Against CD138, Given Weekly for 3 Weeks in Each 4 Week Cycle: Safety and Further Evidence of Clinical Activity

BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity In a Phase I Study In Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

Phase I Study of BT062 Given as Repeated Single Dose Once Every 3 Weeks in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Indatuximab Ravtansine (BT062) In Combination With Lenalidomide and Low-Dose Dexamethasone In Patients With Relapsed and/Or Refractory Multiple Myeloma: Clinical Activity In Len/Dex-Refractory Patients

BT062, an Antibody-Drug Conjugate Directed Against CD138, Given Weekly for 3 Weeks in Each 4 Week Cycle: Safety and Further Evidence of Clinical Activity

BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity In a Phase I Study In Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

Phase I Study of BT062 Given as Repeated Single Dose Once Every 3 Weeks in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only